Deep Brain Stimulation for Parkinson Disease
Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease
See full descriptionAbout the trial for Parkinson Disease
Treatment Groups
This trial involves 2 different treatments. Deep Brain Stimulation is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
About The Treatment
Side Effect Profile for Deep Brain Stimulation
Eligibility
This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Deep Brain Stimulation will improve 3 primary outcomes and 2 secondary outcomes in patients with Parkinson Disease. Measurement will happen over the course of 1 minute test session for each stimulation condition.
Who is running the study
Principal InvestigatorPatient Q & A Section
How many people get parkinson disease a year in the United States?
The National Epidemiological Survey on Alcohol and Related Conditions III (NES-AA) is an effective means of obtaining U.S. prevalence estimates of disorders with high public health and clinical implications. More research is needed to elucidate the relationship of psychosis to disease burden and to improve clinical detection and management of schizophrenia.
Can parkinson disease be cured?
In a large series of patients with PD, the rate of improvement was only 8% and the symptom improvement only 3%, and the percentage of patients fulfilling the minimal criteria for PD remission is low, in the order of 5%.
What causes parkinson disease?
Parkinson disease is a multifactorial disease, characterized by genetic, environmental and intrinsic factors. In order to understand the mechanisms responsible for an individual's susceptibility to PD, the development of new studies is required.
What are common treatments for parkinson disease?
There are three main treatment types: L-DOPA, dopamine agonists, and MAO inhibitors. L-DOPA is usually the drug of choice to treat the motor manifestations of PD. Other drugs may include benserazide, rasagiline, amantadine, and selegiline. Lisdexamfetamine may be used in conjunction with L-DOPA in patients who are not responding well or who have intolerable side effects to L-DOPA. Dopamine agonists may be used as an initial treatment before switching to L-DOPA, but can be ineffective when used alone.
What are the signs of parkinson disease?
At rest, people with PD may have difficulty holding their head still for a prolonged period. As they take their first step, their muscles may seem very weak for a short time before they regain full strength. Other tremors may appear in the fingers as they start moving and in the course of everyday activities. These tremors are usually on one side of the body. Other problems affecting speech or swallowing may also begin. While PD usually affects the lower extremities, Parkinson's disease of the cerebellum causes uncontrollable spasmodic paralysis of the throat, and in rare cases, the eyes. A gradual loss of facial muscle coordination may lead to a grimace or other facial expressions.
What is parkinson disease?
More than one quarter of all cases of Parkinson's disease are associated with a family history of the disease. There is strong support for the autosomal dominant inheritance of the disease and a trend for an increased risk among those of Jewish and Arab ancestry. The symptoms of the disease are fairly specific and are generally consistent with descriptions in the medical literature. The prognosis, depending on the age at onset, is good.
Has deep brain stimulation proven to be more effective than a placebo?
Recent findings indicate that deep brain stimulation delivered at low current improves the motor manifestations of PD. The improvement is correlated to the stage of the disease. DFS, however, leads to further improvements without producing significant side-effects.
Have there been other clinical trials involving deep brain stimulation?
DBS trials and preliminary reports of their efficacy are relatively scarce; however, the reported results represent a trend towards higher stimulation thresholds. This may cause difficulty in the interpretation of the trial results.
How serious can parkinson disease be?
Seriousness of PD as reported by patients and their physicians is associated with some neurologic variables. The severity of PD as reported by patients may be as important as the disease duration of PD when it comes to disability status.
Have there been any new discoveries for treating parkinson disease?
There is no consensus, yet, on the best way to treat PD. A combined approach based on dopaminergic treatment and physical therapy is widely recognized as the most successful one. As for other alternative treatments, there is not much supporting evidence. Nevertheless, this was the first study to the authors knowledge which looked into the potential treatments for parkinson's disease by analysing different cell's therapies in the first time in the world. The most common treatment, the anti-Parkinson drug. Levodopa is commonly used to treat PD, so there may be an effect on the dopamine concentration in a specific area of the brain. We will see how well this is tolerated in a later phase of the study.
Who should consider clinical trials for parkinson disease?
There are important benefits and disadvantages to considering clinical trials for PD, and in evaluating whether to participate in a clinical trial, all the known factors will be taken into consideration.
How does deep brain stimulation work?
[With a high rate of success, DBS can provide long-term symptom relief.] In some cases the surgery can provide complete and durable remission of Parkinson's disease symptoms. It is also a key treatment option for patients who are not candidates for drugs and surgery for Parkinsonism, and can improve both their quality of life and the survival rate. It's recommended to first discuss with your doctors about your treatment options.